Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

408.18 +2.91 (+0.72%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
55 56 Next >
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. 
Via Chartmill
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Markets In A Minute - "A Lack Of Further Progress"
May's FOMC meeting left the Fed Funds Rate unchanged. JOLTS showed fewer job openings with increased layoffs. April's job report disappointed, adding only 175k jobs and seeing higher unemployment.... 
Via Talk Markets
Topics Economy Workforce
Exposures Interest Rates Layoff
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Smart Money Is Betting Big In VRTX Options
Via Benzinga
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
Via Benzinga
2 Fantastic Growth Stocks to Buy Right Now
Don't overlook these high-growth businesses. 
Via The Motley Fool
US Stocks Eye Fourth Positive Session Despite Hawkish Fed Remarks; Disney, Palantir Tumble; Treasury Yields Fall: What's Driving Markets Tuesday?
Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data and minimal updates on earnings from major large-cap companies. 
Via Benzinga
Topics Economy
Exposures Interest Rates
VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
VRTX stock results show that Vertex Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook
Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts. 
Via Investor's Business Daily
Vertex Reports First Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
3 No-Brainer Stocks to Buy in May
These great stocks are great picks for investors as spring winds down. 
Via The Motley Fool
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
Exposures Product Safety
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. 
Via Investor's Business Daily
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar
The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines. 
Via InvestorPlace
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
Via InvestorPlace
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
2 Top Growth Stocks to Buy Right Now and Hold Forever
These healthcare stocks can provide enviable long-term portfolio growth. 
Via The Motley Fool
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.
These three should have a lot of room to run. 
Via The Motley Fool
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers. 
Via Benzinga
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex is broadening its portfolio. 
Via The Motley Fool
Making Sense of Amazon CEO Andy Jassy's Latest Letter
And that's just part of the interesting news for investors to dig into. 
Via The Motley Fool
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
Could Vertex's growth story continue? 
Via The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
These stocks could be near major inflection points. 
Via The Motley Fool
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
These stocks probably won't be getting much cheaper. 
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.